Mass Balance and Biotransformation Study of [14C]DBPR108 in Human

NCT05072028 ↗

Phase 1 Completed 6 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label phase I clinical study to evaluate the mass balance and biotransformation pathways of \[14C\]DBPR108 in Chinese healthy adult male subjects, to reveal the overall pharmacokinetic characteristics of DBPR108 in human body, and to provide a reference for the rational administration.

Timeline

Start: 2021-11-16
Primary completion: 2021-11-28
Completion: 2021-11-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DBPR108	Small molecule	100 mg	Oral

Indications

No indication recorded.